A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan

Trial Profile

A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 06 Sep 2012 Actual initiation date changed from Mar 2012 to Jan 2012 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual patient number (341) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top